<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398668</url>
  </required_header>
  <id_info>
    <org_study_id>SP301</org_study_id>
    <nct_id>NCT03398668</nct_id>
  </id_info>
  <brief_title>Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine</brief_title>
  <official_title>Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolief Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurolief Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the clinical performance and safety of a self administered abortive
      treatment for migraine headache using combined occipital and supraorbital transcutaneous
      nerve stimulator (Neurolief device, Relievion™).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline</measure>
    <time_frame>1 hour</time_frame>
    <description>visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).</measure>
    <time_frame>2 hours</time_frame>
    <description>visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable painbaseline (if rescue therapy was not used).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).</measure>
    <time_frame>24 hours</time_frame>
    <description>Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients not having required rescue medication within 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients not having required rescue medication within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients not having required rescue medication at 2 hours compared to baseline.</measure>
    <time_frame>2 hours</time_frame>
    <description>Proportion of patients not having required rescue medication at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).</measure>
    <time_frame>1, 2, 24 hours</time_frame>
    <description>Proportion of patients pain free at 1,2 and 24 hours from baseline (if rescue therapy was not used).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of &quot;responders&quot; (&quot;responder&quot; is defined as decrease of at least 50% in VAS pain score from baseline) at 1,2 and 24 hours from baseline (if rescue therapy was not used).</measure>
    <time_frame>1, 2, 24 hours</time_frame>
    <description>visual analog scale (VAS) for pain score assessment: 11 point scale 0-no pain, 10-Intolerable pain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints will consist of recording of adverse events and serious adverse events during the study. Device related adverse events will be evaluated between study groups</measure>
    <time_frame>1, 2, 24 hours</time_frame>
    <description>Safety endpoints will consist of recording of adverse events and serious adverse events during the study. Device related adverse events will be evaluated between study groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Relievion device- Treatment stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator: Relievion device- Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Relievion device- Treatment stimulation</intervention_name>
    <description>1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation</description>
    <arm_group_label>Relievion device- Treatment stimulation</arm_group_label>
    <other_name>Neurolief device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Relievion Device- Sham stimulation</intervention_name>
    <description>1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation</description>
    <arm_group_label>Sham Comparator: Relievion device- Sham Stimulation</arm_group_label>
    <other_name>Sham Neurolief device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females Ages of 18 to 65 years old.

          2. History of episodic or chronic migraine with or without aura meeting the diagnostic
             criteria listed in ICHD (International Classification of Headache Disorders)-III beta
             (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e.,
             hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous
             infarction).

          3. Capable to corporate with the study protocol and to sign an informed consent.

        Exclusion Criteria:

          1. Patients having received Botox treatment in the head region in the prior 4 months.

          2. Patients having received supraorbital or occipital nerve blocks in the prior 4 months.

          3. History of Medication Overuse Headache.

          4. Patients using opioid medication.

          5. Allodynia: intolerance to supraorbital and/or occipital neurostimulation that makes
             the treatment not applicable (the patients will be excluded if they are unable to
             tolerate the first 10 minutes of neurostimulation).

          6. Implanted metal or electrical devices in the head (not including dental implants).

          7. Patient having had a previous experience with the Relievion™ device.

          8. Patients who have concomitant epilepsy.

          9. History of neurosurgical interventions.

         10. Patients with implanted neurostimulators, surgical clips (above the shoulder line) or
             any medical pumps.

         11. History of drug abuse or alcoholism.

         12. Participation in current clinical study or participated in a clinical study within 3
             months prior to this study.

         13. Skin lesion or inflammation at the region of the stimulating electrodes.

         14. Personality or somatoform disorder.

         15. Pregnancy or Lactation.

         16. Women with child bearing potential without medically acceptable method of
             contraception.

         17. History of cerebrovascular event.

         18. Subjects with recent brain or facial trauma (occurred less than 3 months prior to this
             study).

         19. Patients using Cannabis

         20. Patients with head circumference smaller than 51 centimeters or head circumference
             larger than 60 centimeters.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dr. Oved, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laniado Medical center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Kedar-Datel</last_name>
    <phone>+972-52-6659806</phone>
    <email>michal.kedar-datel@neurolief.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laniado Medcial Center</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Rosenmann, Mrs.</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Oved, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

